Linno created a Scientific Advisory Board
2021-04-26
Shanghai, April 26th, 2021. Linno Pharmaceuticals Inc. (Linno) today announced the establishment of a scientific advisory committee (SAB), and selected four top experts of their fields as its members.
The four selected Linno SAB members are：
Mingwei Wang, MD., PhD., Director of the National New Drug Screening Center with expertise in G-protein coupled receptors;
Wandong Zhang, MD., PhD., Senior Research Officer at the Human Health Therapeutics Research Centre, National Research Council of Canada, the former Director of Biology and Leader of the Blood-Brain Barrier Program and Head of the Brain Drug Delivery Group at the GlaxoSmithKline (GSK) China R&D Centre (Shanghai);
Dr. H. Eugene Griffin, the former Vice President of Therapeutic Area Head for CureVac, Inc, a Germany-based biotech, former Senior Director at Alexion Pharmaceuticals in R&D and business development, former Senior Director of translational medicine at Veloxis Pharmaceuticals A/S, and former director of preclinical medicine at Biogen and Bristol-Myers；
Dr. Xu Feng, Chief IP Counsel and the assistant Vice President at AstraZeneca China, and a member of AstraZeneca’s Global IP Leadership Team.
Dr. Mingwei Wang will chair the scientific advisory committee. The four members represent top specialists in their fields of pharmacology, neurobiology, ophthalmology, oncology, clinical medicine, and pharmaceutical intellectual property. The advisory committee will dedicate their expertise towards strategic planning and alliance, technology platforms, pipeline development, and international business operation, to better serve Linno’s mission to“work for the needs of patients”.
Zhaozhong (Jack) Han, PhD., Chairman and CEO of Linno, commented : “Since the first day of Linno back around one year ago, the team has made outstanding progress in technical platform development and validation that include drug delivery crossing the blood-brain barrier, and building our scientific expertise in complement biology and rare diseases. With such novel platforms and technologies, multiple therapeutics R&D programs have been in stages of preclinical proof of concept and candidate nomination. I’m very excited to welcome four top specialists to the Scientific Advisory Committee at Linno. Linno will benefit from their professional insights and industrial R&D experience, their expertise will join in the existing capabilities to support the rigorous R&D activities at Linno, to better serve the patients, families, and healthcare providers with more effective and safe treatment options”.